Up to 60% of Crohn disease patients taking an anti—tumor necrosis factor (TNF) monoclonal antibody medication eventually stop responding to treatment, but the optimal management of these patients has not been clearly defined.
Up to 60% of Crohn disease (CD) patients taking an anti—tumor necrosis factor (TNF) monoclonal antibody medication eventually stop responding to treatment, but the optimal management of these patients has not been clearly defined.
A recent review and meta-analysis by Christian Pagnini, MD, PhD, and colleagues, published in Gastroenterology Research and Practice concludes that there is an increasing number of treatment choices for such anti-TNF failures, including using a second anti-TNF monoclonal antibody, and biologics with alternative mechanism of action, such as the anti-integrins vedolizumab (reference biologic, Entyvio) and natalizumab (reference biologic, Tysabri), and the anti-interleukin (IL)-12/IL-23 antibody ustekinumab (reference biologic, Stelara).1 The study found that no specific agent was shown to be clearly superior to others among the only available indirect comparisons currently in the literature.
The analysis relied on 8 randomized, controlled trials (RCTs) involving 1281 CD patients who were treated with biologics and 733 CD patients who received placebo. All 8 RCTs had 2 arms, with one being placebo administration. Anti-TNF treatment failures were defined as patients who failed to respond (primary failure), those who lost their initial response (secondary failure), and those who were forced to discontinue therapy due to toxicity concerns.
Treatment with a second biologic was found to be superior to placebo for both induction of remission (odds ratio [OR] 2.2; 95% confidence interval [CI], 1.7-3) and response (OR 1.9; 95% CI, 1.5-2.5), with global rates of 24% and 42%, respectively (placebo rate: 11% and 27%; P<.0001 for both). Although no specific agent was found to be clearly superior to others, adalimumab performed relatively better with inducing disease remission, followed by vedolizumab.
Further research is needed to identify optimal management strategies for this challenging subset of patients, the study authors note. Because, for several years, anti-TNF inhibitors have been the only available option for biologic treatment (except for natalizumab, which had limited availability), the number of patients in this hard-to-treat group is rapidly increasing, and guidance about their management is an urgent need. Despite the encouraging findings, the authors note that an improved characterization and classification of CD patients is needed, with the aid of relevant molecular biomarkers or clinical features in order to appropriately identify disease phenotypes with specific responses to selected therapeutic regimens.
“The end goal should be a highly tailored therapy with improved efficacy and outcomes in all patients, minimizing unnecessary drug exposure and adverse events,” the authors conclude.
Reference
Pagnini C, Siakavellas SI, Bamias G. Systematic review with network meta-analysis: efficacy of induction therapy with a second biological agent in anti-TNF-experienced Crohn’s disease patients. Gastroenterol Res Pract. 2018; 2018:6317057. doi.org/10.1155/2018/6317057. eCollection 2018.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.